Suggested remit - To appraise the clinical and cost effectiveness of selinexor with low-dose dexamethasone within its marketing authorisation for treating refractory multiple myeloma.
 
Status In progress
Process STA 2018
ID number 1535

Provisional Schedule

Expected publication 26 August 2020
Expected publication 06 January 2021

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 July 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of selinexor with low-dose dexamethasone for treating refractory multiple myeloma . Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-February 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
12 April 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Selinexor with low-dose dexamethasone for treating refractory multiple myeloma . Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early October 2019 when we will write to you about how you can get involved.
09 January 2019 - 06 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 October 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance